PROSTATE CANCER DETECTION BY DNA FINGERPRINTING

功能失调的基因和调控基因的异常表达 推测是人类肿瘤发生的关键事件。在前列腺癌方面， 与许多其他类型的癌症不同，几乎没有一致的基因改变是 检测到。通常，基因改变包括缺失和 发现了某些染色体区域的扩增。其他未定义 癌基因和抑癌基因也可能在前列腺癌中发挥作用 癌症的发展。我们建议检测体细胞的遗传变化 通过聚合酶链式反应技术检测前列腺癌和前列腺癌转移 基于DNA指纹的。在此过程中，使用带有 用任意确定的序列来产生DNA的“指纹” 来自正常和前列腺癌以及来自同一捐赠者的转移。自.以来 在前列腺癌中，DNA序列经常丢失和/或被放大 前列腺癌和转移瘤的指纹应该不同 条带(S)时与相应正常指纹进行比较 同一个体的组织。体细胞基因改变，如 杂合性丢失和染色体获得，两种改变 经常参与非整倍体癌细胞的发展，可以 被这种非常强大的技术检测到。这份提案规定了 恶性相关基因(S)二期鉴定的基础 前列腺癌的进展和转移。 建议的商业应用：这项研究项目具有潜在的 开发独特的肿瘤和/或转移分子标记 而且是专有的。新鉴定的标记可能被用作 前列腺癌易感性的早期诊断探针 前列腺癌的诊断，或作为前列腺癌转移的标志 癌症。

Dysfunctional genes and aberrant expression of regulatory genes are speculated to be key events in human tumorigenesis. In prostate cancer, unlike many other types of cancer, few consistent genetic alterations are detected. Frequently, genetic alterations including deletions and amplifications of certain chromosomal regions are found. Other undefined oncogenes and tumor suppressor genes may also play a role in prostate cancer development. We propose to detect somatic genetic alterations in prostate cancer and prostate metastases through the technique of PCR- based DNA fingerprinting. In this procedure, a single primer with an arbitrarily determined sequence is used to produce "fingerprint" of DNAs from normal and prostate tumor and metastases from the same donor. Since DNA sequences are often lost and/or amplified in prostate cancer, the fingerprints of prostate tumors and metastases should have different band(s) when compared to the fingerprints of the corresponding normal tissue of the same individual. Somatic genetic alterations such as losses of heterozygosity and chromosomal gains, two alterations frequently involved in the development of aneuploidy of cancer cells, can be detected by this very powerful technique. This proposal sets groundwork for Phase II identification of gene(s) involved in malignant progression and metastasis of prostate cancer. PROPOSED COMMERCIAL APPLICATION: This research project has potential for developing tumor and/or metastasis molecular markers that would be unique and proprietary. The newly identified markers could possibly be used as diagnostic probes for the predisposition to prostate cancer, for early diagnosis of prostate cancer, or as a marker of metastasis of prostate cancer.